Clinical Management of Pneumonitis in Patients Receiving Anti–PD-1/PD-L1 Therapy

CASE STUDY A 48-year-old gentleman with metastatic melanoma currently receiving the cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitor, ipilimumab (Yervoy), and the programmed cell death protein 1 (PD-1) inhibitor, nivolumab (Opdivo), returned for evaluation prior to receiving cycle 2. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Bala-Hampton, Justin E., Bazzell, Angela F., Dains, Joyce E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347088/
https://www.ncbi.nlm.nih.gov/pubmed/30719394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347088/
https://www.ncbi.nlm.nih.gov/pubmed/30719394

Ejemplares similares